Introduction
The tumor suppressor gene p53 is the most frequently mutated gene in human cancers (Hollstein et al., 1991; Levine, 1997) p53 is a major player in maintaining the genomic stability of cells. The p53 protein is stabilized and activated in response to a variety of stress signals, such as DNA damage, ultraviolet irradiation, hypoxia, and nucleotide depletion. Such responses trigger important cellular defense functions including growth arrest and apoptosis (Lane and Lain, 2002) . However, in the most human cancer cells, the loss of functional p53 gene impairs the responses of cancer cells to apoptosis induction and leads to poor patient prognosis (Quinlan et al., 1992; Thor et al., 1992) . Cancer gene therapies using ectopic expression of wild-type (wt)-p53 gene to force cancer cells through the apoptotic pathway have been tested extensively preclinically and clinically (Vousden and Lu, 2002) . Numerous in vitro and in vivo reports have proven the feasibility of using adenovirusmediated wt p53 (Ad/p53) to induce apoptosis and kill tumors. Several phase I and phase II clinical trials involving treatment with Ad/p53 in patients with advanced cancers have demonstrated low toxicity, successful gene transfer and evidence of tumor regression (Clayman et al., 1998; Swisher et al., 1999; Nemunaitis et al., 2000) .
p53, a transcription factor, binds to particular p53-binding sites in the promoter regions of genes and activates these genes in a sequence-specific manner (el Deiry et al., 1998) . The two most prominent transcriptional targets of p53 are p21, which is the primary mediator of p53-induced cell cycle arrest (el Deiry et al., 1993; Harper et al., 1993) , and MDM2, which provides feedback regulation of the p53 protein and is clearly involved in many aspects of p53 function (Haupt et al., 1997; Kubbutat et al., 1997) . However, although p53 has been shown to transcriptionally activate a variety of apoptosis-related genes in vitro and in animal tumor models, the effect of p53 on many other p53-dependent and apoptosis-related genes, as well as the mechanism of p53-induced apoptosis in human cancers, is still unclear. The activation of proapoptotic genes, such as Bax and Fas, by p53 appears to be cell-type dependent (Miyashita and Reed, 1995; Friesen et al., 1996) . In various cell types, distinct combinations of activated genes may be required to trigger apoptosis. It is clear that p53-induced apoptosis cannot be attributed to any single gene in all circumstances.
In this study, we used real-time reverse transcriptionpolymerase chain reaction (RT-PCR) to evaluate the changes in expression of some known p53-regulated and apoptosis-related genes in five human non-small-cell lung cancer (NSCLC) cell lines with varying p53 statuses after adenoviral p53 treatment. In addition, to characterize the mechanism of p53-induced apoptosis in human cancers, we used a specific siRNA construct against PUMA mRNA and tested the effect on Ad-p53-mediated apoptosis.
Results

Sensitivity of real-time PCR and RT-PCR
Real-time PCR was recently established as a rapid and sensitive technique for precise quantitation of DNA and RNA. The technique uses the 5 0 exonuclease activity of Taq polymerase, a specific fluorescent probe with a reporter and a quencher dye at each end of the DNA strand, in addition to the standard two PCR primers, for PCR reactions. During the extension phase of the PCR reaction, the probe is cleaved by the 5 0 exonuclease activity of Taq polymerase, releasing the 5 0 reporter dye from the 3 0 quencher dye on the probe. The release of the reporter dye results in a fluorescence signal, which increases exponentially after each PCR cycle. Real-time PCR greatly increases the precision and sensitivity of DNA and RNA quantitation. As shown in Figure 1 , when we designed an Ad/p53-specific probe and used it to determine the copy number of a 10-fold series dilution of Ad/p53 viral DNA, we were able to detect a single copy of viral DNA (equals to about 4 Â 10 À5 pg). When a p53-mRNA-specific probe was designed and used to determine the copy number of a 10-fold series dilution of in vitro T7 RNA polymerase transcribed p53 mRNA by real-time RT-PCR, we detected as few as 10 copies of p53 mRNA (one copy of p53 mRNA equals 6.6 Â 10 À7 pg). The accuracy of the measurements was demonstrated by the clear inverse relationship between threshold cycle (C t ) value and log[DNA] or log[RNA] over the wide range (six orders) of differences in the starting nucleic acid concentration (data not shown).
p53 and p53-regulative or apoptosis-related gene expression in NSCLC cells after Ad/p53 treatment To explore the application of real-time PCR in cancer gene therapy, we used Ad/p53 to infect five human NSCLC cells with varying p53 statuses: H322 (mut), H1299 (null), H358 (null), H460 (wt), and A549 (wt). Ad/LacZ was used as the vector control. The cells were harvested, the RNAs were extracted, and real-time RT-PCR was used to analyse the expression p53 mRNA, p21, MDM2, and other selected p53-regulative or apoptosis-related genes. Figure 2a shows that 24 h after Ad/p53 infection, all five NSCLC cells had dramatic increases in p53 mRNA levels. In addition, the endogenous p53 mRNA levels correlated with the p53 gene statuses: H1299 and H358 were p53 null and had background level p53 mRNA; H460 and A549 are p53 wt and had a noticeable amount of endogenous p53 mRNA; H322, although mutated in the p53 gene, apparently had many aberrant p53 mRNAs, since the primers and probe used could not distinguish wt and mutated p53 mRNAs in the H322 cells.
We next selected a list of known p53-regulative or apoptosis-related genes and performed real-time RT-PCR to determine their mRNA levels. As shown in Figure 2b , the expression of p21, the most prominent p53-regulative gene, was markedly upregulated in all five cell lines; PUMA, a recently identified p53-induced proapoptotic gene, was also dramatically induced in all five cell lines. Expression of the proapoptotic gene Bak increased mildly in H1299 and H358, and Fas expression mildly increased in H358. Further analysis of other genes showed that MDM2 was upregulated in all these cells and that Bax was upregulated similarly to Bak in H1299 and H358 (Table 1) . All the other genes tested, including Bcl-2, Bcl-xL, Bcl-xS, Fas-L, TRAIL, and Ki-67, showed no changes in their mRNA levels under these conditions, that is, 1000 viral particles/cell, 24 h posttreatment.
Since more genes were upregulated in H358 than in the other cells after Ad/p53 treatment and since the upregulation of each gene was more dramatic in H358 cells in the previous experiment, we selected H358 for a kinetic study of gene regulation after Ad/p53 treatment. As shown in Figure 3a , p53 mRNA expression after Ad/ p53 treatment started earlier than 6 h and continued to accumulate until 48 h, falling off noticeably at 72 h. p21 expression changed similarly to that of p53 but with a short delay in response: early upregulation appeared at 12 h, continued until 48 h, and then fell off dramatically at 72 h. PUMA upregulation occurred exactly as did p53 mRNA induction, whereas Fas and Bak mRNA showed much milder increases than did p21 but with distinct kinetics.
To validate these mRNA upregulation findings, we performed a protein analysis of selected genes. As shown in Figure 3b , the fluctuations in the protein levels of these genes corresponded to the changes in mRNA levels: early and strong upregulation of p21 and PUMA, late and mild increases of Bak, Bax, and Fas, and no changes in Bcl-2.
Figure 1 Specificity and accuracy of real-time PCR for Ad/p53 and p53 mRNA detection. Real-time PCR probes were specifically designed for Ad/p53 and p53 mRNA. p53 mRNA was obtained by in vitro transcription using a T7 RNA polymerase. The concentration of Ad/p53 and p53 mRNA was determined by spectrometer and diluted to desired copy numbers. As low as one copy of Ad/p53 was detected. The minimal detection for p53 mRNA was 10 copies. One copy of mRNA was not detected because of the reverse transcription efficiency Induction of p53-regulated genes in lung cancer cells J Gu et al siRNA against PUMA mRNA significantly inhibited PUMA expression, but had little effect on apoptosis A recent study by Yu et al. (2003) showed that PUMA is essential in mediating the apoptotic responses to both exogenous overexpression of p53 and after exposure to hypoxia and DNA damage, physiologic activators of p53, in colorectal cancer cells. PUMA was dramatically induced by Ad-p53 in all of the lung cancer cell lines above; we hypothesized that it might at least partially contribute to Ad-p53-mediated cell killing in lung cancer cells. To test this hypothesis, we used siRNA to block the induction of PUMA upon Ad-p53 treatment. Since different cell lines vary in the efficiency of RNA interference, we first used the MCF7 cell line, which has been shown to be a good mammalian cell system for RNA interference, to test the efficiency of various PUMA siRNA constructs. As shown in Figure 4a , of the three siPUMA constructs (targeting PUMA cDNA sequences from 6 to 24, 622 to 640, and 682 to 700 after the start codon, respectively), siPUMA622 inhibited PUMA expression more than 60%. The transfection efficiency of MCF7 cells is typically about 60-70%; therefore, in those transfected cells, the inhibition efficiency should reach as high as 90% or more. The inhibition of PUMA expression was very specific, with no effects on p53 expression. We designed an siRNA construct against p53 mRNA as a control, and it strongly inhibited p53 expression. As expected, PUMA expression is also inhibited dramatically, confirming that PUMA expression was induced by p53; thus inhibition of p53 led to a reduction of PUMA expression.
To apply siPUMA to the lung cancer cell lines in our study, we first tested their RNA interference efficiency. The RNAi efficiency of siRNA in the H358 and A549 Ad/p53 induces p53 mRNA and downstream gene expression in a cell-type dependent manner. Cells were treated with 1000 MOI Ad/p53 or AdLacZ for 24 h and harvested for total RNA isolation. Real-time RT-PCR was performed as described in Materials and methods. (a) The absolute p53 mRNA copy number (in 100 ng of total RNA) was determined by comparing samples with the standard curved generated, as in Figure 1 . (b) The relative mRNA upregulation was determined by comparing with the mRNA level of PBS-treated cells, which was arbitrarily set as 1. The mRNA level of each gene was normalized with the level of GAPDH mRNA. Each experiment was repeated at least twice Induction of p53-regulated genes in lung cancer cells J Gu et al cells was very low; the H460 cells were difficult to transfect: only about 10% of the cells were transfected when the GFP plasmid was used as the control (data not shown). H1299 was the best lung cancer cell lines in which to test siRNA effects, in that both its RNAi and transfection efficiencies were very high. As shown in Figure 4b , siPUMA620 inhibited PUMA expression, and siP53 inhibited both Ad/p53-induced p53 expression and PUMA expression. However, no detectable difference in apoptosis percentage was found between the control and the siPUMA620 treatment, whereas the siP53 treatment noticeably inhibited apoptosis since the amount of p53 protein was greatly reduced.
Discussion
These data suggested that ectopic p53 overexpression upregulates several proapoptotic genes and that lack of induction in one of them will not block p53-mediated apoptosis. The p53 protein is a powerful transcription factor that binds to the p53-binding sites within the promoter region of a large number of genes and regulates their expression (Fields and Jang, 1990; Kern et al., 1991; el Deiry et al., 1992) . Wang et al. (2001) analysed the existing human genome using a bioinformatic approach and found that 4852 genes contain at least one consensus p53-binding site. Using cDNA microarrays, they further experimentally identified that 1501 genes, among 33 615 unique human genes available, respond to adenoviral p53 treatment. In another study, Zhao et al. (2000) used oligonucleotide microarrays to analyse p53-regulated gene expression in a colon cancer cell line, EB-1, carrying a wt-p53 gene under the control of an inducible promoter. Of 6000 genes examined, 107 were activated and 54 were repressed upon p53 induction. The products of these genes have different cellular functions, including growth arrest, DNA repair, apoptosis, oxidative stress response, stimulation or suppression of cell division, cell adhesion, and angiogenesis. The two most prominent outcomes of p53 protein activation are cell cycle arrest and apoptotic cell death. It is clear that sequence-specific transcriptional transactivation, most notably of p21, by p53 protein is essential for cell cycle arrest (Brugarolas et al., 1995; Deng et al., 1995) . However, whether transcriptional activity of p53 is obligatory for apoptosis is still controversial. There have been reports of p53-induced apoptosis in the absence of its transcription activity (Caelles et al., 1994; Haupt et al., 1995) . Nevertheless, the overwhelming view among researchers is that p53 primarily induces apoptosis as a transcriptional regulator, at least under certain physiological conditions, that is, a wide range of genotoxic stresses that cause cells to increase endogenous cellular p53 protein levels and activity. The elevated p53 proteins transactivate or repress hundreds of genes that collectively lead cells to apoptosis. But because so many genes are altered after p53 induction, it is difficult to determine which event is the most critical in causing cell death. Complicating the issue are the enormous cell type and tissue type differences in the spectrum of genes regulated by p53. Even in the same cell lines, different stresses, such as ultraviolet damage and g-irradiation, have been shown to induce markedly different gene expressions with only a small subset in common (Zhao et al., 2000) .
A rapidly growing number of proapoptotic genes have been convincingly shown to be upregulated by p53 protein. The first reported p53-regulated proapoptotic gene, Bax, was initially found to be unnecessary for radiation-induced, p53-dependent apoptosis in mouse thymocytes (Knudson et al., 1995) , although it is involved in p53-mediated neuronal cell death (Xiang et al., 1998) . Later, a double knockout of Bax and the closely related Bak gene showed that p53-dependent apoptosis in mouse thymocytes was completely abrogated, suggesting that Bax does play a role in p53-dependent apoptosis in this cell type but that its function is redundant with that of Bak (Lindsten et al., 2000) . Similarly, the death receptor Fas, is also unnecessary for radiation-induced, p53-dependent apoptosis of mouse thymocytes (Reinke and Lozano, 1997), but it contributes largely to drug-induced apoptosis in leukemia cells (Friesen et al., 1996) . The past 3 years have witnessed the cloning of several novel p53-regulated proapoptotic genes: PUMA, NOXA, p53AIP, PIDD, and others (Lin et al., 2000; Oda et al., 2000a, b; Nakano and Vousden, 2001; Yu et al., 2001) . Although all of these genes are required for p53-mediated apoptosis in some cell systems, no single target gene has been identified as pivotal to the apoptotic pathway in general. Given the rapidly growing list of p53-regulative proapoptotic genes, it would be a daunting task to distinguish which genes contribute and to what extent, to the p53-induced apoptosis in each cell type using traditional mouse gene knockout experiments.
The recent revolutionary discovery of RNA interference and the development of related techniques has provided a powerful tool for rapid reverse genetics. Genes can now be easily knocked out in cultured cells. In this study, we first used a rapid and sensitive real-time PCR technique to screen genes induced by Ad/p53 overexpression in five different human lung cancer cell lines. Our data confirmed the complexity of gene expression patterns upon p53 induction. We then tested whether one of the most significantly upregulated genes, PUMA, contributed to Ad/p53-caused apoptosis. Our data suggest that although PUMA was markedly induced, its defect does not block p53-induced apoptosis in lung cancer cells, since its inhibition by siPUMA did not attenuate apoptosis in H1299 cells. Our results are different from that reported by Yu et al. (2003) who used a gene-targeting approach to completely knockout p21, PUMA, or the both genes in a colorectal cancer cell line HCT116. Their results showed that parental HCT116 was resistant to apoptosis induction by Ad/ p53. However, p21 À/À HCT116 was sensitive to Ad/p53-mediated apoptosis whereas the double knockout p21 À/ À , PUMA À/À HCT116 was not, suggesting that PUMA was critical in p53-mediated apoptosis. Here we used the lung cancer cell line H1299 that has the wt p21 and PUMA genes and is susceptible to apoptosis induction by Ad/p53. However, blocking p53-mediated PUMA expression by siRNA was not sufficient to block p53-mediated apoptosis. It is not clear whether basal level of PUMA expression or whether different genetic background is critical for the difference between our results and that observed by Yu et al. (2003) . Interestingly, p53-mediated upregulations of the Bax and Bak genes were observed in H1299 cells but not in p21
HCT116 cells. As treatment of Ad/p53 also resulted in upregulation of Bax and Bak genes, it remains to be tested whether lack of induction in the Bax, Bak, or Fas gene will dramatically block p53-mediated apoptosis. It is likely that the simultaneous knockout of several of them would be required to block p53-mediated apoptosis. It is also possible that some unidentified p53-inducible genes are involved in Ad/p53-mediated apoptosis. Although adenoviral p53 also induces the expression of a similar spectrum of proapoptotic genes as endogenously induced p53 expression, the contribution of these genes to apoptosis may be less than that of stress-induced p53-dependent genes. Exceedingly high levels of p53 can repress general transcription from many promoters (Seto et al., 1992; Mack et al., 1993) and can cause a rapid disruption of the mitochondrial integrity and rapid release of cytochrome c (Polyak et al., 1997) , all of which may take place earlier than the increase of proapoptotic gene expression and may mask the effects of these genes. Further systematic studies to elucidate complete cellular changes after adenoviral p53 treatment in each experimental system are clearly warranted. The mechanisms behind Ad/p53-induced apoptosis could be more than just induction of a few proapoptotic genes.
Materials and methods
Cell lines
Five human NSCLC cell lines were used in this study: H1299 and H358 cells are p53-deleted; H322 has a mutated p53 gene; H460 and A549 have wt p53. All cells lines were purchased from the American Type Culture Collection (Rockville, MD, USA) and maintained in our lab in RPMI 1640 supplemented with either 5% (H1299 and H358) or 10% fetal calf serum (H322, H460, and A549) and were incubated at 371C in a 5% CO 2 incubator.
Adenovirus production and in vitro gene transfer
The construction and properties of the replication-defective adenovirus, Ad/p53, have been reported previously (Zhang et al., 1993) . An adenovirus encoding the lacZ gene (Ad/LacZ) was used as a control vector. Virus titers were determined by optical absorbance at A 260 (OD 260 , one A 260 unit ¼ 10 12 particles/ml) and by plaque assay. Titers determined by OD 260 (i.e., viral particles) were used in all the experiments. Particle/plaque ratios normally fell between 30 : 1 and 100 : 1. All viral preparations were free of contamination by E1 þ adenoviruses and endotoxins.
Real-time PCR and RT-PCR
Sequences for the primers and probes are available upon request. The probe and primer sets for each gene were designed around the junction region of two exons, using the Primer Express software (version 1.0, Perkin-Elmer Inc.), so that they are mRNA-specific. For quantitative real-time RT-PCR, human total RNA was used as a relative standard, and human GAPDH gene was used as an internal control for relative mRNA amount. Real-time PCR was performed using the ABI Prism 7700 Sequence Detection System according to the protocol of the manufacturer. Typical amplification mixes (25 ml) contained the sample DNA (or cDNA), 10 Â TaqMan buffer (2.5 ml), 200 mM dATP, dCTP, dGTP, and 400 mM dUTP, 5 mM MgCl 2 , 0.65 U of AmpliTaq Gold, 0.25 U of AmpErase uracil N-glycosylase, 200 nM each primer and 100 nM probe. The thermal cycling conditions consisted of one cycle for 2 min at 501C and for 10 min at 951C, and 50 cycles for 15 s at 951C and for 1 min at 601C. All reactions were performed in duplicate.
After the reaction, the built-in software in the 7700 system analysed all the data and generated the standard curve, the threshold cycle (C t ) value of each testing sample, and the corresponding starting quantity of each based on the standard curve. The value in each experiment was an average of duplicated samples. All experiments were repeated at least twice.
Western blot analysis
Cells were collected at various time points after infection with Ad/p53 or Ad/LacZ, and lysates were prepared. In all, 100 mg of total cellular proteins were separated electrophoretically using 10-12% sodium dodecyl sulfate (SDS)-polyacrylamide gels and then transferred to Hybond-enhanced chemiluminescence membranes (Amersham Corp., Arlington Heights, IL, USA). Membranes were then blocked with blocking buffer containing 5% low-fat milk and 0.05% Tween-20 in phosphate-buffered saline (PBS) for 1 h at room temperature or overnight at 41C, washed three times with PBS containing 0.05% Tween-20 (PBST), and then incubated with primary antibodies for 3 h at room temperature or overnight at 41C. After being washed with PBST again, the membranes were incubated with peroxidase-conjugated secondary antibodies for 1 h at room temperature and developed with an enhanced chemiluminescence detection kit (ECL kit, Amersham Pharmacia Biotech, Piscataway, NJ, USA). The antibodies used were: mouse anti-human p53 and p21 (PharMingen, San Diego, CA, USA), rabbit anti-human Bak, Bax, Bcl-2, Bcl-X S/ L , Fas, and MDM2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-human PUMA (Abcam Limited, Cambridge, UK), and mouse anti-human b-actin (Sigma Chemical Co., St Louis, MO, USA).
siRNA construct and transfection siRNA plasmids against GFP, PUMA, and p53 were constructed using the pSilencer 1.0-U6. Vector (Ambion, Inc., Austin, TX, USA) backbone plasmid. Briefly, small hairpin siRNA sequences were synthesized as two complementary DNA oligonucleotides and annealed; the result was a short double-stranded DNA with ApaI and EcoRI on either end; the DNA was ligated to pSilencer plasmids, which were digested with ApaI and EcoRI. The target sequences used for the siRNA constructs were p53, GACTCCAGTGGTAATC-TAC; GFP, GAAGTCGTGCTGCTTCATG; and PUMA, TCTCATCATGGGACTCCTG. The resulting siRNA constructs were named siP53, siGFP, and siPUMA. They were transfected into cells using liposome FuGENE 6 (Roche Diagnostics Corporation, Indianapolis, IN, USA), and 48 or 72 h later, the cells were harvested for either Western blot analysis or apoptosis analysis.
